Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | GLP1R | P43220 | 1/20 | 0.60 |
| ▸ | GCGR | P47871 | 1/20 | 0.60 |
| ▸ | GIPR | P48546 | 1/20 | 0.60 |
| ▸ | IL23R | Q5VWK5 | 11/20 | 0.58 |
| ▸ | PTH1R | Q03431 | 5/20 | 0.57 |
| ▸ | GRPR | P30550 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16265092 | 1.00 | RXFP1 (0.62) | RXFP1GLP1RGCGRGIPRIL23R | |
| SCHEMBL12026383 | 0.92 | RXFP1 (0.69) | RXFP1GLP1RGCGRGIPRIL23R | |
| SCHEMBL12026389 | 0.92 | RXFP1 (0.69) | RXFP1GLP1RGCGRGIPRIL23R | |
| SCHEMBL12026378 | 0.90 | IL23R (0.69) | RXFP1GLP1RGCGRGIPRIL23R | |
| SCHEMBL12026377 | 0.90 | IL23R (0.69) | RXFP1GLP1RGCGRGIPRIL23R | |
| SCHEMBL12026379 | 0.88 | IL23R (0.68) | RXFP1IL23RPTH1R | |
| SCHEMBL12026380 | 0.88 | IL23R (0.68) | RXFP1IL23RPTH1R | |
| SCHEMBL16265094 | 0.88 | IL23R (0.64) | IL23R | |
| SCHEMBL12026376 | 0.87 | IL23R (0.69) | RXFP1IL23R | |
| SCHEMBL12026385 | 0.87 | IL23R (0.69) | RXFP1IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349949-A1 | HYALURONIC ACID CONTAINING COMPOSITIONS FOR TREATMENT OF WOUNDS, SCARS, POST-SURGICAL ADHESION FORMATION | PERGAMUM AB (SE) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349949-A1 | HYALURONIC ACID CONTAINING COMPOSITIONS FOR TREATMENT OF WOUNDS, SCARS, POST-SURGICAL ADHESION FORMATION | CD44, HDGF, FIBP | RXFP1 377/4885GLP1R 1967/4885GCGR 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.